New Antibody-Drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT06224673

Recruiting now Disease control Sponsor: Laura Huppert, MD, BA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARX788 (Anvatabart Opadotin)
What this could lead to: If successful, this could provide a new treatment option for patients with HER2-low breast cancer that has spread or cannot be removed by surgery.
What could go wrong: This is an early Phase II trial with only 36 participants, so results may not apply to all patients. Side effects from the drug or eye toxicity are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 LOW BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2 LOW BREAST CARCINOMA HORMONE RECEPTOR POSITIVE BREAST CANCER HORMONE RECEPTOR POSITIVE BREAST CARCINOMA TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.